# Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

> **NCT04557956** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 16 (actual)

## Conditions studied

- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Metastatic Melanoma

## Interventions

- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Computed Tomography
- **DRUG:** Dabrafenib Mesylate
- **PROCEDURE:** Echocardiography Test
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Multigated Acquisition Scan
- **DRUG:** Tazemetostat Hydrobromide
- **DRUG:** Trametinib Dimethyl Sulfoxide

## Key facts

- **NCT ID:** NCT04557956
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-19
- **Primary completion:** 2025-10-15
- **Final completion:** 2027-03-11
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04557956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04557956, "Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04557956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*